Novartis India launches Pluvicto for PSMA-positive metastatic prostate cancer
Radioligand therapy approved for eligible patients with PSMA-positive prostate cancer in India
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Novartis India
Elevated Lp(a) raises CVD risk: Global experts call for action
Ahead of World Heart Day (29 September), Global Heart Hub and Novartis convened international healthcare experts for the…
Novartis India concludes NEST 2025, recognising emerging talent in healthcare innovation
The competition awarded four winning teams from a prize pool of INR 8,00,000, offering pre-placement interview opportunities with…
Novartis India extends access to its medicines in India with Dr Reddy’s Laboratories
This brings together the manufacturing and development synergies of Novartis with the sales and distribution strengths of Dr…
Embracing the power of data
The pharma sector needs to improve its capabilities in data gathering and analysis with the help of AI and computational…
Novartis India extends medical cover to all employees equally
Insurance benefit plans will be extended to LGBTI, single parents, live-in partners and their dependent children
Novartis India…
SPJIMR launches programme for NGOs working in cancer care
The one-of-its-kind programme will cover four modules to be conducted over two days each in the month of May, August, November…
KTR inaugurates Novartis Knowledge City
The Novartis Knowledge City in Hyderabad is clearly not just a testament to the value proposition offered by the Hyderabad NGSC.…
Delhi HC tells govt not to take coercive steps against pharma cos
Petitions were filed by pharma companies and an association of medicine manufacturing firms challenging the government's new drug…
Novartis India posts results for quarter ended June 30, 2015
The company registered net profit after other income of Rs 13.5 crore
The Board of Novartis India approved the results for the…